Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet-activating factor does not induce bronchial hyperreactivity in nonasthmatic subjects.

I Gebremichael1, P Leuenberger

  • 1Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Respiration; International Review of Thoracic Diseases
|January 1, 1992
PubMed
Summary

Inhaling platelet-activating factor (PAF) did not cause bronchial hyperresponsiveness in healthy individuals. This study found no significant changes in airway reactivity after PAF administration, suggesting it doesn't induce asthma-like symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pneumology. Anti-IgE antibodies in the treatment of asthma].

Revue medicale suisse·2007
Same author

[Bronchial neoplasm in man and women: two distinct illnesses?].

Revue medicale suisse·2007
Same author

Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study.

Thorax·2006
Same author

[Pneumonology. Ultrasound-guided transbronchial needle aspiration].

Revue medicale suisse·2006
Same author

[Pneumology. Treatment of idiopathic pulmonary fibrosis: hopes and disappointment].

Revue medicale suisse·2005
Same author

Management of chronic obstructive pulmonary disease: the Swiss guidelines. Official Guidelines of the Swiss Respiratory Society.

Swiss medical weekly·2002

Area of Science:

  • Respiratory Medicine
  • Inflammation Research
  • Pharmacology

Background:

  • Platelet-activating factor (PAF) is a mediator of inflammation.
  • PAF has been linked to bronchial hyperresponsiveness in humans.
  • Understanding PAF's effect on airway reactivity is crucial for respiratory health.

Purpose of the Study:

  • To investigate the effect of inhaled platelet-activating factor (PAF) on bronchial reactivity in normal subjects.
  • To determine if PAF induces bronchial hyperresponsiveness.
  • To assess changes in airway function following PAF inhalation.

Main Methods:

  • Six healthy subjects inhaled cumulative doses of 400 micrograms of PAF.
  • Forced expiratory flows (FEF) were measured during PAF inhalation.

Related Experiment Videos

  • Bronchial reactivity to methacholine (MCH) was assessed at intervals up to 21 days post-PAF.

    • Main Results:

    • Subjects reported mild side effects like hot flush and tracheal irritation.
    • No significant changes in forced expiratory flows were observed during PAF inhalation.
    • Bronchial reactivity to methacholine remained unchanged at all measured time points after PAF exposure.

    Conclusions:

    • Inhaled PAF, at tolerable doses, does not induce bronchial hyperresponsiveness in healthy individuals.
    • Neither a 20% reduction in FEV1 nor changes in FEF25-75% and FEF75% indicated hyperresponsiveness.
    • PAF inhalation does not appear to alter airway reactivity in the short term.